PBYI - חובות ארוכי טווח של החברה pumabiotechnology.com

The financial stability of Puma Biotechnology (PBYI) relies on the sales of a single oncology drug, which leaves cash flows vulnerable due to a lack of diversification, and the metric stands at 0.00. The company's price action reflects the dynamics of a business whose developments are created in California, while drug manufacturing is delegated to external US contractors. However, falling demand for the core product limits organic growth, necessitating strict oversight of investments in new projects.

Investors are assessing the potential of Puma Biotechnology (PBYI) through the lens of the company's ability to service its long-term obligations. This metric aggregates all loans and borrowings with a maturity of more than one year, reflecting the level of debt load on capital. By analyzing the company's long-term debt, one can identify the risks of cash flow gaps given the low diversification of revenue from a single drug. Stable demand for the medication mitigates the pressure of liabilities, confirming the issuer's moderate financial stability.